Please note that the ANZCTR website will be unavailable from 6pm until 6.30pm (AEST) on Monday 22nd July for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Prospectively registered

Titles & IDs
Public title
Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in the Kobeni site (provide of Hodh El Gharbi) and Timbedra (Hodgh Echargui province), Mauritania
Scientific title
A study evaluating the efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in the Kobeni site (provide of Hodh El Gharbi) and Timbedra (Hodgh Echargui province), Mauritania
Secondary ID [1] 283807 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Malaria 290784 0
Condition category
Condition code
Infection 291150 291150 0 0
Other infectious diseases

Study type
Description of intervention(s) / exposure
Artemether-lumefantrine will be administered according to body weight, twice a day over 3 days. Tablets containing 20mg base of artemether and 120 mg base of lumefantrine will be administered orally. The number of tablets administered is based on the weight of the patient, twice a day, over three days – 1 tablet for patients of 5-14kg, 2 for patients of 15-24kg, 3 for patients of 25-34kg, 4 over 34kg. All doses of medicine will be administered under the supervision of a qualified member of the staff designated by the principal investigator. The study patients will be observed for 30 min after medicine administration for adverse reactions or vomiting. Any patient who vomits
during this observation period will be re-treated with the same dose of medicine and observed for an additional 30 min. If the patient vomits again, he or she will be withdrawn and offered rescue therapy. Clinical and parasitological parameters will be monitored over a 28-day follow-up period to evaluate drug efficacy.
Intervention code [1] 290033 0
Treatment: Drugs
Comparator / control treatment
No control
Control group

Primary outcome [1] 292934 0
The study end-point is the classification assigned to a patient. Valid study end-points include: treatment failure, completion of the follow-up period without treatment failure (adequate clinical and parasitological response), loss to follow-up, withdrawal from study, and protocol violation. At all times, the well-being of the patient will take priority over his or her continuation in the study. Treatment outcomes will be classified on the basis of an assessment of the parasitological and clinical outcome of antimalarial treatment according to the latest WHO guidelines. Thus, all patients will be classified as having early treatment failure, late clinical failure, late parasitological failure or an adequate clinical and parasitological response.
Timepoint [1] 292934 0
A standard physical examination will be performed at baseline (day 0 before dosing) and on days 1, 2, 3, 7, 14, 21 and 28. A complete medical history, including prior and concomitant medication, demographic information and contact details will be recorded at baseline.
Secondary outcome [1] 309977 0
Timepoint [1] 309977 0

Key inclusion criteria
Age above 6 months; Mono infection with P. falciparum confirmed by positive blood smear (i.e. no mixed infection), parasitaemia between 1000 and 100000 microliters of asexual forms; measured temperature equal or great than 37.5 degrees celcius (depending on method of measurement) or history of fever within previous 24 hours; ability to swallow oral medication; ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; consent to take part in the study (or parental consent/guardian consent if less than 18 years old); and the absence of severe malnutrition.
Minimum age
6 Months
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
Signs and symptoms of severe or complicated malaria according to the definitions of WHO; mixed or mono-infection with another Plasmodium species detected by microscopy; presence of severe malnutrition; febrile conditions due to diseases other than malaria or other know underlying chronic or severe diseases; regular medication which interferes with antimalarial pharmacokinetics; history of hypersensitivity reactions or contraindications to the medicine(s) being tested; positive pregnancy test or breastfeedings; unable to or unwilling to use contraception, including abstinence, for women of child-bearing age and who are sexually active.

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Subjects are those with malaria seeking treatment, please see inclusion criteria for further information.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
no specific sequence, all subjects have same treatment.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Phase 3 / Phase 4
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Not yet recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment outside Australia
Country [1] 6294 0
State/province [1] 6294 0
Hodh El Gharbi
Country [2] 6295 0
State/province [2] 6295 0
Hodh Echargui

Funding & Sponsors
Funding source category [1] 289788 0
Name [1] 289788 0
World Health Organization
Address [1] 289788 0
Avenue Appia 20
CH 1211 Geneva 20
Country [1] 289788 0
Primary sponsor type
Government body
Ministry of Health
Monsieur le Ministre Ahmedou Hademine Jelvoune
BP 169 Nouakchott-Mauritanie
Secondary sponsor category [1] 288478 0
Name [1] 288478 0
Address [1] 288478 0
Country [1] 288478 0

Ethics approval
Ethics application status
Ethics committee name [1] 291525 0
Ethics Review Committee, World Health Organization
Ethics committee address [1] 291525 0
Avenue Appia 20
CH 1211 Geneva 20
Ethics committee country [1] 291525 0
Date submitted for ethics approval [1] 291525 0
Approval date [1] 291525 0
Ethics approval number [1] 291525 0

Brief summary
To study the efficacy of antimalarial drugs in Mauritania
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 45134 0
Dr Mohamed Lemine Ould KHAIRY
Address 45134 0
Programme National de Lutte contre le Paludisme
Ministere de la Sante
Ilot A 52, Tevragh Zeina,

Country 45134 0
Phone 45134 0
+222 22 68 44 49
Fax 45134 0
Email 45134 0
Contact person for public queries
Name 45135 0
Dr Mohamed Lemine Ould KHAIRY
Address 45135 0
Programme National de Lutte contre le Paludisme
Ministere de la Sante
Ilot A 52, Tevragh Zeina,

Country 45135 0
Phone 45135 0
+222 22 68 44 49
Fax 45135 0
Email 45135 0
Contact person for scientific queries
Name 45136 0
Dr Mohamed Lemine Ould KHAIRY
Address 45136 0
Programme National de Lutte contre le Paludisme
Ministere de la Sante
Ilot A 52, Tevragh Zeina,

Country 45136 0
Phone 45136 0
+222 22 68 44 49
Fax 45136 0
Email 45136 0

No information has been provided regarding IPD availability
Summary results
No Results